Identifying innovative ideas to turn them into new business opportunities
Actelion has a dedicated team focused on identifying innovation from external sources that complements our business approach. Once identified, Actelion is rapid, proactive and open in creating benefits for both parties. We commit ourselves to the project we share with our partner, to make the product a global success.
Actelion / Auxilium Pharmaceuticals, Inc. collaboration
Actelion and Auxilium entered into a collaboration in February 2012 to develop, supply and commercialize XIAFLEX® (collagenase clostridium histolyticum), a novel, first-in-class biologic for the potential treatment of Dupuytren’s contracture and Peyronie’s disease. Under the terms of the agreement, Actelion will receive exclusive rights to commercialize XIAFLEX for the treatment of Dupuytren’s contracture and Peyronie’s disease in Canada, Australia, Brazil and Mexico upon receipt of the respective regulatory approvals. Actelion will be primarily responsible for the applicable regulatory and commercialization activities for XIAFLEX in these countries. Actelion will pay Auxilium an upfront payment of $10 million and will also make up to $16 million in potential regulatory, pricing and reimbursement milestone payments and $42.5 million in potential sales milestone payments. Auxilium will also receive increasing tiered double-digit royalties based on sales of XIAFLEX in Actelion’ territories and will supply product to Actelion at a predetermined cost.
In July 2012, Auxilium was granted a Notice of Compliance (approval) by Health Canada for XIAFLEX, for the treatment of Dupuytren’s contracture in adults with a palpable cord in Canada. Actelion expects to make XIAFLEX available to patients in Canada in the first half of 2013.
Actelion / Nippon Shinyaku alliance
Actelion and Nippon Shinyaku entered into an exclusive worldwide alliance in April 2008 to collaborate on an orally-available long-acting prostaglandin I2 (PGI2) receptor agonist for patients suffering from pulmonary arterial hypertension (PAH). This compound was originally discovered and synthesized by Nippon Shinyaku. Phase I evaluation has recently been completed, and a Phase II program in PAH patients was initiated by Nippon Shinyaku in Europe at the end of 2007. Actelion will be responsible for global development and commercialization of the PGI2 receptor agonist outside Japan, while the two companies will co-develop and co-commercialize in Japan.
Actelion / Bayer Schering Pharma AG alliance
Actelion holds the exclusive US rights for inhaled iloprost, marketed under the brand name Ventavis®, an inhaled treatment for pulmonary arterial hypertension (PAH), licensed from Bayer Schering Pharma AG (through the acquisition of CoTherix Inc.). Actelion has the US development responsibilities, and has established a joint Development and Commercialization Committee for future collaboration with Bayer Schering Pharma AG. Actelion books all sales of Ventavis® in the US, and pays a royalty on sales to Bayer Schering Pharma AG. In addition to this royalty, Actelion is contractually required to pay one final milestone payment to Bayer Schering Pharma AG upon achieving a set sales target.
Actelion / Oxford GlycoSciences alliance
In November 2002, Actelion in-licensed miglustat, the active ingredient of Zavesca®, from Oxford GlycoSciences (UK) Ltd. Zavesca came to the market in the European Union in March 2003, followed by the United States in January 2004. In November 2005, Actelion entered an agreement with UCB S.A., the legal successor to Oxford GlycoSciences under wich UCB S.A. assigned all rights and obligations regarding miglustat, including worldwide marketing rights, to Actelion (except in Israel, the West Bank and the Gaza Strip).